secwatch.observer — SEC 8-K summary
======================================

Issuer:     Voyager Therapeutics, Inc. (VYGR)
CIK:        0001640266
Form:       8-K
Filed at:   2023-02-23T23:59:59+00:00
Accession:  0001104659-23-024436
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Voyager Therapeutics SVP & General Counsel Robert Hesslein to depart April 28, 2023
--------------------------------------------------------------------------------

- Robert Hesslein resigns as SVP and General Counsel effective April 28, 2023; transition period until then.
- Severance includes 12 months salary continuation, prorated 2023 bonus ($180,302 target), and COBRA premium payments for 12 months.
- Post-separation consulting agreement through Sept 30, 2023; unvested RSUs and stock options continue vesting during consulting term.
- Hesslein signs release of claims, reaffirms confidentiality and non-solicitation obligations, and agrees to non-disparagement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1640266/000110465923024436/0001104659-23-024436-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1640266/000110465923024436/tm237527d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-024436

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer